{
    "clinical_study": {
        "@rank": "48617", 
        "arm_group": [
            {
                "arm_group_label": "A: Peg-interferon alpha-2a & Ribavirin", 
                "arm_group_type": "Active Comparator", 
                "description": "Arm A: PEGASYS\u00ae 180 ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks."
            }, 
            {
                "arm_group_label": "B: Peg-interferon alpha-2a & Ribavirin", 
                "arm_group_type": "Experimental", 
                "description": "Arm B: PEGASYS\u00ae 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks.\n(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
            }, 
            {
                "arm_group_label": "C: Peg-interferon alpha-2a & Ribavirin", 
                "arm_group_type": "Experimental", 
                "description": "Arm C: PEGASYS\u00ae 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.\n(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
            }, 
            {
                "arm_group_label": "D: Peg-interferon alpha-2a & Ribavirin", 
                "arm_group_type": "Active Comparator", 
                "description": "Arm D: PEGASYS\u00ae 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.\n(Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment)"
            }, 
            {
                "arm_group_label": "E: Peg-interferon alpha-2a & Ribavirin", 
                "arm_group_type": "Experimental", 
                "description": "Arm E: PEGASYS\u00ae 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.\n(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
            }, 
            {
                "arm_group_label": "F: Peg-interferon alpha-2a & Ribavirin", 
                "arm_group_type": "Experimental", 
                "description": "Arm F: PEGASYS\u00ae 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks.\n(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purposes of this study are:\n\n        1. To test if 36 weeks of standard dose of ribavirin with PEGASYS\u00ae is non-inferior to\n           standard dose of 48 weeks of ribavirin with PEGASYS\u00ae in SVR for patients with RVR and\n           HVL\n\n        2. To test if the 72 weeks of treatment with PEGASYS\u00ae plus standard dose ribavirin is\n           superior to 48 weeks of the same treatment for patients with HCV RNA seropositivity at\n           week 12"
        }, 
        "brief_title": "Tailored Regimens of PEGASYS\u00ae and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The aims of the present study are:\n\n        1. To evaluate the efficacy and safety of 36-week versus 48-week regimen of PEGASYS\u00ae\n           (peginterferon alfa-2a, PegIFN) plus standard-dose of ribavirin (RBV) in hepatitis C\n           virus (HCV) genotype 1 infected, treatment-na\u00efve CHC patients who have high viral loads\n           (HVL, defined as baseline HCV RNA \u2267 400,000 IU/mL) and achieve a rapid virologic\n           response (RVR) (defined as seronegativity of HCV RNA at week 4 of treatment)\n\n        2. To evaluate the efficacy and safety of 48-week versus 72-week regimen of PegIFN plus\n           standard-dose of RBV in HCV virus genotype  1 infected, treatment-na\u00efve CHC patients\n           with PCR-seropositive of HCV RNA at  week 12"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients *18 years of age\n\n          -  Patients have never been treated with traditional interferon plus ribavirin or\n             peginterferon plus ribavirin\n\n          -  Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test\n\n          -  Detectable serum HCV-RNA and HCV viral genotype 1\n\n          -  Liver biopsy findings consistent with the diagnosis of chronic hepatitis C infection\n             with or without compensated cirrhosis (Exception: hemophiliacs in whom biopsy is\n             medically contra-indicated do not require biopsy.)\n\n          -  Compensated liver disease (Child-Pugh Grade A clinical classification)\n\n          -  Negative urine or blood pregnancy test (for women of childbearing potential)\n             documented within the 24-hour period prior to the first dose of study drug\n\n          -  All fertile males and females receiving ribavirin must be using two forms of\n             effective contraception during treatment and during the 6 months after treatment end\n\n        Exclusion Criteria:\n\n          -  Women with ongoing pregnancy or breast feeding\n\n          -  Therapy with any systemic anti-neoplastic or immunomodulatory treatment (including\n             supraphysiologic doses of steroids and radiation) *6 months prior to the first dose\n             of study drug\n\n          -  Any investigational drug *6 weeks prior to the first dose of study drug\n\n          -  Co-infection with active hepatitis A, hepatitis B and/or human immunodeficiency virus\n             (HIV)\n\n          -  History or other evidence of a medical condition associated with chronic liver\n             disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver\n             disease, alcoholic liver disease, toxin exposures)\n\n          -  Signs or symptoms of hepatocellular carcinoma\n\n          -  History or other evidence of bleeding from esophageal varices or other conditions\n             consistent with decompensated liver disease\n\n          -  Neutrophil count <1500 cells/mm3 or platelet count <90,000 cells/mm3 at screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937728", 
            "org_study_id": "KMUH-IRB-970119"
        }, 
        "intervention": [
            {
                "arm_group_label": "A: Peg-interferon alpha-2a & Ribavirin", 
                "description": "Arm A: Patients who have low viral loads (LVL, defined as baseline HCV RNA < 400,000 IU/mL) and RVR will be treated with PEGASYS 180ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.", 
                "intervention_name": "A: Peg-interferon alpha-2a & Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Pegasys & Robatrol"
            }, 
            {
                "arm_group_label": "B: Peg-interferon alpha-2a & Ribavirin", 
                "description": "Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.\nArm B: PEGASYS\u00ae 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks.", 
                "intervention_name": "B: Peg-interferon alpha-2a & Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Pegasys & Robatrol"
            }, 
            {
                "arm_group_label": "C: Peg-interferon alpha-2a & Ribavirin", 
                "description": "Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.\nArm C: PEGASYS\u00ae 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.", 
                "intervention_name": "C: Peg-interferon alpha-2a & Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Pegasys, Robatrol"
            }, 
            {
                "arm_group_label": "D: Peg-interferon alpha-2a & Ribavirin", 
                "description": "Arm D: Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment will be treated with PEGASYS\u00ae 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.", 
                "intervention_name": "D: Peg-interferon alpha-2a & Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "PEGASYS, Robatrol"
            }, 
            {
                "arm_group_label": "E: Peg-interferon alpha-2a & Ribavirin", 
                "description": "Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.\nArm E: PEGASYS\u00ae 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.", 
                "intervention_name": "E: Peg-interferon alpha-2a & Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Pegasys, Robatrol"
            }, 
            {
                "arm_group_label": "F: Peg-interferon alpha-2a & Ribavirin", 
                "description": "Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.\nArm F: PEGASYS\u00ae 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks.", 
                "intervention_name": "F: Peg-interferon alpha-2a & Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Pegasys, Robatrol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Ribavirin", 
                "Peginterferon alfa-2a"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatitis C", 
            "Genotype 1", 
            "Peg interferon", 
            "alfa 1a", 
            "Ribavirin"
        ], 
        "lastchanged_date": "September 4, 2013", 
        "location": {
            "contact": {
                "email": "daichiayen@gmail.com", 
                "last_name": "Chia-Yen Dai", 
                "phone": "886 7-312 1101", 
                "phone_ext": "7475"
            }, 
            "facility": {
                "address": {
                    "city": "Kaohsiung", 
                    "country": "Taiwan"
                }, 
                "name": "Kaohsiung Medical University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Randomized, Multicenter, Open Label Study Evaluating the Efficacy and Safety of Tailored Regimens With Peginterferon Alfa-2a Plus Ribavirin According Viral Kinetics for Genotype 1 Chronic Hepatitis C Patients", 
        "overall_contact": {
            "email": "research.kmuhb@gmail.com", 
            "last_name": "Chia-Yen Dai", 
            "phone": "886 7-312 1101", 
            "phone_ext": "7475"
        }, 
        "overall_contact_backup": {
            "email": "daichiayen@gmail.com", 
            "last_name": "Chia-Yen Dai", 
            "phone": "886 7-312 1101", 
            "phone_ext": "7475"
        }, 
        "overall_official": {
            "affiliation": "Kaohsiung Medical University", 
            "last_name": "Chia-Yen Dai, M.D., PhD.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4 Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "24-week off-treatment period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937728"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kaohsiung Medical University Chung-Ho Memorial Hospital", 
            "investigator_full_name": "Chia-Yen Dai", 
            "investigator_title": "Professor, School of Medicine, Hepatology Division", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "adverse event rate and profile", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "24-week off-treatment period"
        }, 
        "source": "Kaohsiung Medical University Chung-Ho Memorial Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kaohsiung Medical University Chung-Ho Memorial Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}